Wills Financial Group Inc. Raises Stake in Kenvue Inc. (NYSE:KVUE)

Wills Financial Group Inc. lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 15.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 280,606 shares of the company’s stock after buying an additional 38,340 shares during the period. Kenvue accounts for approximately 2.6% of Wills Financial Group Inc.’s portfolio, making the stock its 11th largest holding. Wills Financial Group Inc.’s holdings in Kenvue were worth $5,991,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC purchased a new position in shares of Kenvue during the 4th quarter worth about $5,117,000. Coldstream Capital Management Inc. increased its position in Kenvue by 2.5% during the fourth quarter. Coldstream Capital Management Inc. now owns 26,673 shares of the company’s stock worth $569,000 after purchasing an additional 656 shares during the last quarter. Voya Investment Management LLC raised its stake in Kenvue by 22.1% during the fourth quarter. Voya Investment Management LLC now owns 5,244,684 shares of the company’s stock worth $111,974,000 after purchasing an additional 950,315 shares during the period. Sirios Capital Management L P acquired a new position in shares of Kenvue in the 4th quarter valued at $423,000. Finally, MGO One Seven LLC grew its stake in shares of Kenvue by 12.2% during the 4th quarter. MGO One Seven LLC now owns 37,771 shares of the company’s stock valued at $806,000 after buying an additional 4,116 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.03 on Friday. The business has a 50 day moving average price of $23.03 and a two-hundred day moving average price of $22.43. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a market cap of $44.19 billion, a PE ratio of 43.45, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.56%. The ex-dividend date is Wednesday, May 14th. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on KVUE shares. Barclays reduced their target price on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, April 14th. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 target price for the company. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Finally, Citigroup raised their target price on shares of Kenvue from $21.00 to $22.00 and gave the company a “neutral” rating in a research note on Monday, April 14th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.